


DEVELOPMENTS IN MICROBIOLOGY

IMMUNOPATHOLOGY, DIAGNOSIS,
AND TREATMENT OF
HPV-INDUCED MALIGNANCIES



Edited by
Prashant Khare
Ashish Jain



**IMMUNOPATHOLOGY,
DIAGNOSIS, AND
TREATMENT OF
HPV-INDUCED
MALIGNANCIES**

This page intentionally left blank

Developments in
Microbiology

**IMMUNOPATHOLOGY,
DIAGNOSIS, AND
TREATMENT OF
HPV-INDUCED
MALIGNANCIES**

Edited by

PRASHANT KHARE

Department of Microbiology, All India Institute of Medical
Sciences Bhopal, Bhopal, Madhya Pradesh, India

ASHISH JAIN

Department of Microbiology, Smt. Chandibai Himathmal
Mansukhani College (affiliated with the University of
Mumbai), Ulhasnagar, Maharashtra, India



ELSEVIER



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2022 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN 978-0-323-91797-1

For information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Stacy Masucci
Acquisitions Editor: Linda Versteeg-Buschman
Editorial Project Manager: Tim Eslava
Production Project Manager: Niranjan Bhaskaran
Cover Designer: Greg Harris

Typeset by STRAIVE, India



Contents

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xi</i>
1. An overview of HPV: Causes, symptoms, and clinical manifestations	1
Anuj Tripathi and Utkarsha Sahu	
1. Introduction	1
2. Structure and biology of HPV	3
3. Causes of HPV infection	4
4. HPV symptoms	5
5. HPV diagnosis	5
6. Clinical manifestation of HPV infections	7
7. Prevention of HPV infection	10
8. Wart treatment	11
9. HPV vaccines	11
10. Conclusion	12
References	13
2. Pathogenesis and immune response against HPV infection	21
Utkarsha Sahu and Prashant Khare	
1. Introduction	21
2. Pathogenesis and immune response associated with HPV infection	22
3. Evasion of host immune response	30
4. Conclusion	32
References	34
3. Malignancies associated with HPV	43
Prashant Kumar Tiwari, Divya Kushwaha, and Ambuj Kumar Kushwaha	
1. Introduction	43
2. Malignancies associated with HPV	46
3. Treatment of HPV-associated malignancies	55
4. Conclusion	56
Acknowledgment	56
References	57

4. Immunological aspects of HPV/HIV co-infection and risk of gynecological diseases	65
Amrita Srivastava, Priyanka Namdev, and Rajaneesh Anupam	
1. Introduction	65
2. Immunological aspects of HPV infection	68
3. The impact of immunological aspects of HPV on HIV infection	70
4. HPV-HIV co-infections and gynecological disorders	72
5. Conclusion	75
References	76
5. Cervicovaginal microbiota and HPV-induced cervical cancer	81
Ashish Jain, Swadesh Kishore Shrivastava, and Linju Joy	
1. Introduction	81
2. Human papillomavirus (HPV)	82
3. Cervicovaginal microbiota (CVM)	83
4. CVM, sexually transmitted infections (STIs), and CC	86
5. Restoration of CVM to prevent CC	90
6. Conclusion	90
References	91
6. Current diagnostic tools for HPV	99
Aneesh Sethu Madhavan, Deepti Joshi, Tanya Sharma, Shashwati Nema, and Debasis Biswas	
1. Introduction	99
2. Diagnostic techniques for HPV infection	100
3. Screening strategies	112
4. Conclusion	115
References	115
7. Animal models for the discovery of therapeutic and prophylactic measure against HPV-induced malignancies	119
Shobha Upreti and Mukesh Samant	
1. Introduction	119
2. Animal models for therapeutic and prophylactic measures against HPV	121
3. Conclusion	125
References	126

8. Potential drug targets against HPV and repurposing of existing drugs	129
Utkarsha Sahu, Prashant Khare, and Ashvini Yadav	
1. Introduction	129
2. Potential drug targets against HPV	130
3. Repurposing of existing drugs against HPV	137
4. Conclusion	141
References	143
9. Recent advances and strategies in vaccine development against HPV	149
Anoop Kumar and Praveen Rai	
1. Introduction	149
2. Requirement and type of HPV vaccine	151
3. Candidate for the HPV vaccine development	152
4. Licensed vaccines against HPV	153
5. Development of the future HPV vaccine	153
6. The future of HPV vaccination	160
7. Conclusion	160
References	160
10. Available immunotherapies and future opportunities to prevent HPV-associated cancers	165
Rohit Kumar Tiwari, Afza Ahmad, Irfan Ahmad Ansari, and Preeti Bajpai	
1. Introduction	165
2. Present therapeutic options for HPV-associated cancers	168
3. Immunotherapies for HPV-associated cancers	169
4. CC	170
5. HNSCC	181
6. Oral cancer	190
7. Conclusion	192
References	192
<i>Index</i>	205

CHAPTER 10

Available immunotherapies and future opportunities to prevent HPV-associated cancers

Rohit Kumar Tiwari^a, Afza Ahmad^a, Irfan Ahmad Ansari^a,
and Preeti Bajpai^b

^aDepartment of Biosciences, Integral University, Lucknow, Uttar Pradesh, India

^bDepartment of Zoology, Mahatma Gandhi Central University, Motihari, Bihar, India

1. Introduction

Several forms of malignancies including cervix, vagina, vulva, head and neck, and penile are commonly associated with human papillomavirus (HPV) [1]. More than 100 HPV variants have been identified to date [2]. Of these, the most frequently encountered high-risk HPV (HR-HPV) variants (16, 18, 31, and 45) are together responsible for approximately 80% of cervical cancer (CC) cases [3–5]. Among several other variants, HPV-16 and -18 are considered as most pervasive HPV variants that are linked with an estimated 62.6% and 15.7% of several malignancies, respectively [6]. Intriguingly, these stated variants are responsible for <85% of vaginal and vulvar, ~90% of oropharyngeal, 93% of anal as well as ~80% of penile carcinomas [7]. HPV infection in women accounts for an alarming situation globally as its infection increases the risk of developing cancer [8], thus making HPV a current public health priority (Fig. 1). Approximately 291 million HPV-positive incidences were reported globally in 2007 [9]. In the women exhibiting homeostatic cytology of the cervix, the prevalence of HPV infection was 10.4% and 11.7% between 2007 and 2010, respectively. Ethnically, increased reports of HPV infection were reported in women belonging to Oceania (30.9%), Africa (slightly more than 20%), persuaded by Europe (14.2%), America (11.5%), and Asia (9.4%) [10,11]. Moreover, among the female population globally, 32.1% were reported to be the carriers of HPV infection in 2011 whereas the females belonging to Asia and Africa demonstrated higher prevalence of 45.5% and 29.6%, respectively [12].